Beihai Kangcheng, a leading company in the treatment of rare diseases in China, successfully listed on the main board of Hong Kong

As the earliest investor, Qiming Venture Capital led Beihai Kangcheng's Series A financing in 2014 and continued to support it in the Series B financing

Beihai Kangcheng is a leading global biopharmaceutical company based in China and focusing on rare diseases.

At present, Beihai Kangcheng has built a comprehensive pipeline consisting of 13 drug assets, including 3 marketed products, 4 drug candidates in the clinical stage, 1 in the IND preparation stage, 2 in the preclinical stage, and 3 in the preclinical stage.

Dr.

Chen Kan, Executive Director of Qiming Ventures, said: “The team led by Dr.

About Qiming Venture Capital

Qiming Venture Capital was established in 2006 and has successively set up offices in Shanghai, Beijing, Suzhou, Hong Kong, Seattle, Boston and San Francisco Bay Area

At present, Qiming Venture Capital manages ten US dollar funds and six RMB funds, with a total of 6.

Up to now, Qiming Ventures has invested in more than 430 fast-growing innovative companies, of which more than 170 are traded on the New York Stock Exchange, Nasdaq, Hong Kong Stock Exchange, Taiwan OTC, Shanghai Stock Exchange and Shenzhen Stock Exchange.

Among Qiming Venture Capital's investment companies, many have grown into the most influential companies in their respective fields, including Xiaomi Group (01810.